Lee Wei-Chieh, Fang Hsiu-Yu
Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan,
Division of Cardiology, Cardiac Care Unit, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan,
Cardiology. 2019;144(3-4):97-100. doi: 10.1159/000502475. Epub 2019 Sep 18.
Ivabradine is used as a second-line medication for chronic heart failure (HF) but is still off-label for acute HF. We report the case of a 50-year-old man who experienced infectious endocarditis-related acute severe mitral regurgitation (MR) and acute decompensated HF and showed quick improvement of clinical symptoms after ivabradine use. An unstable hemodynamic status does not allow titration of a β-blocker dose, and a β-agonist might be needed to overcome a critical condition. Ivabradine appears to solve this issue and protect the myocardium owing to prolongation of the diastolic perfusion time. Ivabradine might be useful for the treatment of acute severe MR-related acute decompensated HF due to the improvement of diastolic function by decreasing the heart rate.
伊伐布雷定被用作慢性心力衰竭(HF)的二线药物,但在急性HF治疗中仍属于超说明书用药。我们报告了一例50岁男性患者,该患者患有感染性心内膜炎相关的急性重度二尖瓣反流(MR)和急性失代偿性HF,使用伊伐布雷定后临床症状迅速改善。不稳定的血流动力学状态不允许滴定β受体阻滞剂剂量,可能需要使用β受体激动剂来克服危急情况。伊伐布雷定似乎可以解决这个问题,并通过延长舒张期灌注时间来保护心肌。由于降低心率改善了舒张功能,伊伐布雷定可能对治疗急性重度MR相关的急性失代偿性HF有用。